BIOTRONIK Neuro’s Post

Every three seconds, someone in the world is impacted by a stroke, and the World Stroke Organization reports that 101 million people are living with its consequences. May is #NationalStrokeAwarenessMonth and we at Siemens Healthineers are deeply committed to the fight against this global health challenge. We invite you to explore our integrated stroke solutions, see how we streamline stroke workflows to address potential challenges. Join us on this journey to shape the future of stroke care. Together, we can make a significant difference. For effective stroke treatment and positive patient outcomes, every second counts. Healthcare professionals are dedicated to establishing the fastest possible diagnosis and treatment pathways for their patients. A seamless treatment journey is critical for delivering optimal care and for preventing further incidents. Our imaging technologies play a pivotal role in a variety of stroke scenarios, helping to identify conditions. Moreover, our ARTIS icono is instrumental in supporting the continuum of care with endovascular treatments. 🎥 Watch our informative video now! https://lnkd.in/emhqMtv7 #StrokeCare #HealthcareInnovation #SiemensHealthineers 

Every three seconds, someone somewhere in the world is affected by a stroke, and according to the World Stroke Organization, 101 million people are living with the aftermath of a stroke. For an optimized stroke treatment and a good patient outcome, time is of the essence. Healthcare practitioners aim to set up the ideal pathway for fast diagnosis and treatment of their patients. A well-coordinated treatment pathway is essential for optimal care and prevention to reduce the recurrence rate. Imaging technologies assist in a wide range of stroke scenarios identifying conditions such as blood clots, carotid plaques or a vessel ruptures, while our ARTIS icono therapy device plays a key role in supporting the continuum of care through endovascular treatment. Explore our integrated stroke solutions to see how to streamline a stroke workflow to overcome possible constraints. 🎥 Watch our informative video now! https://lnkd.in/d7vFhSBJ #StrokeCare #HealthcareInnovation #SiemensHealthineers 

Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation

In the latest Vivid Magazine, GE HealthCare explores the prognostic value of myocardial work. Dr. Jing Yao explains how she’s applying the method to make clinical decisions about Cardiac Resynchronization Therapy. Dive in today! #Vivid #VividMagazine #myocardialwork #CRT #echocardiography #GEHealthCare #CardiovascularUltrasound #CardiovascularHealth #Ultrasound #HeartHealth

Today, we reached a milestone by celebrating our 100th DVT/PE thrombectomy case. A dedicated PERT team has been instrumental in our success. The continuous advancements in thrombectomy devices and management of pulmonary embolism and deep vein thrombosis have significantly improved patient outcomes and operational efficiency. The evolution in this field has been a game-changer, offering reduced complications, enhanced efficiency, and improved usability. Excitingly, more studies and innovative devices are on the horizon, promising further advancements in the near future. This progress parallels previous eras of medical advancements, such as the stent era in the early 2000s and the structural heart era in the 2010s. Now, the 2020s mark the era of venous thromboembolism. Here's to continued growth and innovation in the VTE era! #MedicalInnovations #Thrombectomy #PERTTeam #HealthcareAdvancements

In the latest Vivid Magazine, GE HealthCare explores the prognostic value of myocardial work. Dr. Jing Yao explains how she’s applying the method to make clinical decisions about Cardiac Resynchronization Therapy. Dive in today! #Vivid #VividMagazine #myocardialwork #CRT #echocardiography #GEHealthCare #CardiovascularUltrasound #CardiovascularHealth #Ultrasound #HeartHealth

Do you want to take a chance that your patient may lose MR eligibility due to impedance conditions? A recent study showed that is what happened with 43% of non-Medtronic SureScan™ SCS patients† at five years post-implant.(1) With Medtronic SureScan™ systems, 100% of SCS patients have MR access regardless of impedance.‡ Stop by our booth or join us for our lunch symposium where industry leaders, Drs. Chris Beuer, Krishnan Chakravarthy, Samir Sheth, Ricardo Vallejo, and Thomas White, will review the broad comprehensive pain product portfolio, unmatched MRI access§, and discuss clinical outcomes. #MDTPainInterventions #SCS #NANS2024 #NANS24 #MRI #PatientsFirst †Abbott, Boston Scientific, and Nevro ‡ Assuming all other conditions are met § Under specific conditions. Refer to product labeling for full list of conditions. (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

🌟 Home OCT is transforming #AMD management! Dr. Miguel Busquets reveals groundbreaking insights with Home OCT, providing a personalized view of fluid recurrence in neovascular AMD. This innovative tool influences timely and individualized treatment, showcasing significant fluid dynamics heterogeneity for optimized patient care and vision maintenance. Learn more in this article from Healio by Michela Cimberle, fact checked by Christine Klimanskis #amd #agerelatedmaculardegeneration #maculardegeneration #cataract #ophthalmology #ophthalmologynews

𝗔𝗜-𝗲𝗻𝗮𝗯𝗹𝗲𝗱 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝘁𝗼𝗼𝗹 𝗰𝗮𝗻 𝗱𝗲𝘁𝗲𝗰𝘁 𝗹𝗼𝘄 𝗲𝗷𝗲𝗰𝘁𝗶𝗼𝗻 𝗳𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗷𝘂𝘀𝘁 𝟭𝟱 𝘀𝗲𝗰𝗼𝗻𝗱𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝘀 𝗙𝗗𝗔 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 Eko Health has received FDA clearance for its AI-enabled cardiac tool, ELEFT. This tool can detect low ejection fraction in just 15 seconds during a routine exam using an Eko stethoscope. This tool is part of Eko's SENSORA Cardiac Early Detection Platform and aims to help clinicians identify patients at risk of heart failure, particularly in underserved communities. Other companies in the tech-enabled heart health space include CardioSignal and Ultromics, which are showing a growing trend in AI-based solutions for cardiac care. Source: https://lnkd.in/gVDBA83z

How are new products changing the way we treat glaucoma patients? Please see attached the link to the recording of the interventional glaucoma symposium hosted at the APAO 2024 in Bali earlier this year. Presenter Prof. Shamira Perera (Singapore) explores this question with Prof. Michell Lawlor (Australia), Prof. Tina Wong (Singapore), Dr. Colin Clement (AU), Dr. Leonard Yip (SG), Dr. Robert Ang (PH) and Dr. Bryan Ang (SG) at the APAO 2024 Glaukos Dinner Symposium. The experts dive deep into the proactive approach to interventional glaucoma, focusing on early diagnostics and intervention, along with patient noncompliance with treatment, slow-release medication devices, SLT as the first line of treatment and more. https://lnkd.in/gVPRbm_h Great discussions amongst some of the biggest names in glaucoma in our region.